These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 33707236)

  • 1. Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity.
    Mahadevan NR; Knelson EH; Wolff JO; Vajdi A; Saigí M; Campisi M; Hong D; Thai TC; Piel B; Han S; Reinhold BB; Duke-Cohan JS; Poitras MJ; Taus LJ; Lizotte PH; Portell A; Quadros V; Santucci AD; Murayama T; Cañadas I; Kitajima S; Akitsu A; Fridrikh M; Watanabe H; Reardon B; Gokhale PC; Paweletz CP; Awad MM; Van Allen EM; Lako A; Wang XT; Chen B; Hong F; Sholl LM; Tolstorukov MY; Pfaff K; Jänne PA; Gjini E; Edwards R; Rodig S; Reinherz EL; Oser MG; Barbie DA
    Cancer Discov; 2021 Aug; 11(8):1952-1969. PubMed ID: 33707236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer.
    Hong D; Knelson EH; Li Y; Durmaz YT; Gao W; Walton E; Vajdi A; Thai T; Sticco-Ivins M; Sabet AH; Jones KL; Schinzel AC; Bronson RT; Nguyen QD; Tolstorukov MY; Vivero M; Signoretti S; Barbie DA; Oser MG
    Cancer Res; 2022 Jan; 82(2):248-263. PubMed ID: 34810201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC.
    Nguyen EM; Taniguchi H; Chan JM; Zhan YA; Chen X; Qiu J; de Stanchina E; Allaj V; Shah NS; Uddin F; Manoj P; Liu M; Cai SF; Levine R; Quintanal-Villalonga Á; Sen T; Chow A; Rudin CM
    J Thorac Oncol; 2022 Aug; 17(8):1014-1031. PubMed ID: 35691495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
    Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
    Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC.
    Taniguchi H; Caeser R; Chavan SS; Zhan YA; Chow A; Manoj P; Uddin F; Kitai H; Qu R; Hayatt O; Shah NS; Quintanal Villalonga Á; Allaj V; Nguyen EM; Chan J; Michel AO; Mukae H; de Stanchina E; Rudin CM; Sen T
    Cell Rep; 2022 May; 39(7):110814. PubMed ID: 35584676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing.
    Hiatt JB; Sandborg H; Garrison SM; Arnold HU; Liao SY; Norton JP; Friesen TJ; Wu F; Sutherland KD; Rienhoff HY; Martins R; Houghton AM; Srivastava S; MacPherson D
    Clin Cancer Res; 2022 Oct; 28(20):4551-4564. PubMed ID: 35920742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer.
    Taniguchi H; Chakraborty S; Takahashi N; Banerjee A; Caeser R; Zhan YA; Tischfield SE; Chow A; Nguyen EM; Villalonga ÁQ; Manoj P; Shah NS; Rosario S; Hayatt O; Qu R; de Stanchina E; Chan J; Mukae H; Thomas A; Rudin CM; Sen T
    Sci Adv; 2024 Sep; 10(39):eado4618. PubMed ID: 39331709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of small-cell lung cancer associates with STING pathway activation and is enhanced by ATR and TOP1 inhibition.
    Li X; Li Y; Zhao Z; Miao N; Liu G; Deng L; Wei S; Hou J
    Cancer Med; 2023 Feb; 12(4):4864-4881. PubMed ID: 35957613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation.
    Rudin CM; Balli D; Lai WV; Richards AL; Nguyen E; Egger JV; Choudhury NJ; Sen T; Chow A; Poirier JT; Geese WJ; Hellmann MD; Forslund A
    J Thorac Oncol; 2023 Sep; 18(9):1222-1232. PubMed ID: 37210008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes.
    Kursunel MA; Taskiran EZ; Tavukcuoglu E; Yanik H; Demirag F; Karaosmanoglu B; Ozbay FG; Uner A; Esendagli D; Kizilgoz D; Yilmaz U; Esendagli G
    Cancer Immunol Immunother; 2022 Feb; 71(2):445-459. PubMed ID: 34228218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution.
    Dora D; Rivard C; Yu H; Bunn P; Suda K; Ren S; Lueke Pickard S; Laszlo V; Harko T; Megyesfalvi Z; Moldvay J; Hirsch FR; Dome B; Lohinai Z
    Mol Oncol; 2020 Sep; 14(9):1947-1965. PubMed ID: 32506804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer.
    Roper N; Velez MJ; Chiappori A; Kim YS; Wei JS; Sindiri S; Takahashi N; Mulford D; Kumar S; Ylaya K; Trindade C; Manukyan I; Brown AL; Trepel JB; Lee JM; Hewitt S; Khan J; Thomas A
    Nat Commun; 2021 Jun; 12(1):3880. PubMed ID: 34162872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer.
    Cai L; Liu H; Huang F; Fujimoto J; Girard L; Chen J; Li Y; Zhang YA; Deb D; Stastny V; Pozo K; Kuo CS; Jia G; Yang C; Zou W; Alomar A; Huffman K; Papari-Zareei M; Yang L; Drapkin B; Akbay EA; Shames DS; Wistuba II; Wang T; Johnson JE; Xiao G; DeBerardinis RJ; Minna JD; Xie Y; Gazdar AF
    Commun Biol; 2021 Mar; 4(1):314. PubMed ID: 33750914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis.
    Zhu M; Huang Y; Bender ME; Girard L; Kollipara R; Eglenen-Polat B; Naito Y; Savage TK; Huffman KE; Koyama S; Kumanogoh A; Minna JD; Johnson JE; Akbay EA
    Cancer Res; 2021 Apr; 81(7):1813-1826. PubMed ID: 33495232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival.
    Kellish P; Shabashvili D; Rahman MM; Nawab A; Guijarro MV; Zhang M; Cao C; Moussatche N; Boyle T; Antonia S; Reinhard M; Hartzell C; Jantz M; Mehta HJ; McFadden G; Kaye FJ; Zajac-Kaye M
    J Clin Invest; 2019 Apr; 129(6):2279-2292. PubMed ID: 31033480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Facts and Hopes on Cancer Immunotherapy for Small Cell Lung Cancer.
    Zugazagoitia J; Osma H; Baena J; Ucero AC; Paz-Ares L
    Clin Cancer Res; 2024 Jul; 30(14):2872-2883. PubMed ID: 38630789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
    Reddy HG; Qin A; Kalemkerian GP
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of CD38 in anti-tumor immunity of small cell lung cancer.
    Taniguchi H; Chavan SS; Chow A; Chan JM; Mukae H; Rudin CM; Sen T
    Front Immunol; 2024; 15():1348982. PubMed ID: 38533509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unexpected Synergy Reveals New Therapeutic Strategy in SCLC.
    Drapkin BJ; Farago AF
    Trends Pharmacol Sci; 2019 May; 40(5):295-297. PubMed ID: 30975441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new small cell lung cancer (SCLC)-specific marker discovered through antigenic subtraction of neuroblastoma cells.
    Krueger P; Nitz C; Foster R; MacDonald C; Gelber O; Lalehzadeh G; Goodson R; Winter J; Gelber C
    Cancer Immunol Immunother; 2003 Jun; 52(6):367-77. PubMed ID: 12669243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.